By The comments made by a Johnson & Johnson executive earlier this week about biotechnology valuations calls attention to the struggling biotech sector.
: Biotech stocks had a challenging year, but that doesn’t mean they’re ‘necessarily on sale,’ J&J exec tells investors
Comments